HIV Prevention Trials Network

Studies

HPTN Studies

HPTN research studies are developed by protocol teams that include CTU investigators and recognized experts in HIV prevention. As study protocols are developed, they undergo a rigorous intra- and extra-network review process that ensures compliance with current ethical guidelines and regulatory procedures.

To view detailed information about studies, including performance sites and enrollment figures, select a protocol number from the tables below.  Each Study Protocol is available once version 1.0 is approved and distributed to the performance sites.  The CORE Protocol Contact can provide additional information and materials.

 

Ongoing Studies and Studies in Development

Protocol Number Protocol Title Status

HPTN 027

10141

A Phase I Study to Evaluate the Safety and Immunogenicity of ALVAC-HIV vCP1521 in Infants Born to HIV-1 Infected Women in Uganda

Closed to Accrual

HPTN 039-01

10067

Ancillary Study: Prospective Cohort Study of HPTN 039 Seroconverters: The Effect of HSV-2 Suppression on HIV-1 Viral Set Point

Closed to Accrual

HPTN 043

 

A Phase III Randomized Controlled Trial of Community Mobilization, Mobile Testing, Same-Day Results, and Post-Test Support for HIV in Sub-Saharan Africa and Thailand

Enrolling

HPTN 046

10142

Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV Infected Women to Prevent Vertical HIV Transmission During Breastfeeding

Enrolling

HPTN 052

10068

A Randomized Trial to Evaluate the Effectiveness of Antiretroviral Therapy Plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples

Enrolling

HPTN 057

10143

A Phase I Open Label Trial of the Safety and Pharmacokinetics of Tenofovir Disoproxil Fumarate in HIV-1 Infected Pregnant Women and their Infants

Enrolling

HPTN 058

10144

A Phase III randomized controlled trial to evaluate the efficacy of drug treatment in prevention of HIV infection and death among opiate dependent injectors

Enrolling

HPTN 061

10666

Feasibility of a community-level, multi-component intervention for Black MSM in preparation for a Phase IIB community-level randomized trial to test the efficacy of the intervention in reducing HIV incidence among Black MSM

Enrolling

HPTN 062

10667

Feasibility and Acceptability Study of an Individual-Level Behavioral Intervention for Individuals with Acute and Early HIV-Infection

Pending

HPTN 063

10668

Preparing for international prevention trials involving HIV-infected individuals in care settings

Pending

HPTN 064

10705

The Women’s HIV SeroIncidence Study (ISIS)

Enrolling

HPTN 065

10841

TNT-Plus: A Study to Evaluate the Feasibility of an Enhanced Test-and-Treat Approach for the Prevention of HIV Transmission in the United States

In Development

HPTN 066

10851

Dose-Proportionality and Intra-Individual Variability of Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate in Healthy Volunteers

In Development

HPTN 067

10852

Behavioral Aspects of PrEP Counseling for Intermittent Exposure

In Development

 

Completed Studies

Protocol Number Protocol Title Status

HIVNET 012

 

A Phase IIB Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates

Participants Off Study & Primary Analysis Complete

HIVNET 015

 

EXPLORE: A Randomized Clinical Trial of the Efficacy of a Behavioral Intervention to Prevent Acquisition of HIV among Men who have Sex with Men (MSM)

Concluded

HIVNET 016A

 

Condom Promotion and Counseling Study

Concluded

HIVNET 024

 

Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission

Participants Off Study & Primary Analysis Complete

HPTN 032

 

Male Tolerance Study of BufferGel and PRO 2000/5 Gel (P)

Concluded

HPTN 033

 

HIV Prevention Preparedness Study

Concluded

HPTN 034

10199

HIV Incidence and Participant Retention Protocol, Pune, India

Concluded

HPTN 035

10065

Phase II/IIb Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and 0.5% PRO2000/5 Gel (P) for the Prevention of HIV Infection in Women

Closed to Follow Up

HPTN 036

 

HIV Prevalence, Incidence, and HSV-2 Prevalence Among High-Risk MSM in Perú

Concluded

HPTN 037

10125

A Phase III Randomized Study to Evaluate the Efficacy of a Network-oriented Peer Educator Intervention for the Prevention of HIV Transmission Among Injection Drug Users And Their Network Members

Participants Off Study & Primary Analysis Complete

HPTN 039

10066

A Phase III, randomized, double-blind, placebo-controlled trial of acyclovir for the reduction of HIV acquisition among high risk HSV-2 seropositive, HIV-seronegative individuals

Participants Off Study & Primary Analysis Complete

HPTN 047

 

A Phase I Safety and Acceptability Study of the Investigational Vaginal Microbicide PRO 2000/5 Gel (P)

Concluded

HPTN 049

 

Phase I Safety and Acceptability Study of the Vaginal Microbicide 6% Cellulose Sulfate Gel Among HIV-Infected Women

Concluded

HPTN 050

 

Phase I Safety and Acceptability Study of the Vaginal Microbicide Agent PMPA Gel

Concluded

HPTN 055

 

HIV Prevention Preparedness Study

Concluded

HPTN 056

 

Characterization of Baseline Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials

Concluded

HPTN 059

10145

Phase II Expanded Safety and Acceptability Study of the Vaginal Microbicide 1% Tenofovir Gel

Concluded

Site Map | HPTN Disclaimer | Webmaster | ©2008 Family Health International